Loss of the 14-3-3σ tumor suppressor is a critical event in ErbB2-mediated tumor progression

Cancer Discovery
Chen LingWilliam J Muller

Abstract

14-3-3σ is a putative tumor suppressor involved in cell-cycle progression and epithelial polarity. We demonstrate that loss of one or both copies of the conditional 14-3-3σ allele results in accelerated mammary and salivary tumorigenesis in mice expressing an activated erbB2 oncogene under the endogenous erbB2 promoter. Significantly, the majority of tumors bearing a single conditional 14-3-3σ allele lose expression of the remaining 14-3-3σ allele, which is associated with epigenetic methylation of the 14-3-3σ locus. In addition to accelerated tumor onset, in a mouse mammary tumor virus-driven ErbB2 tumor model, loss of 14-3-3σ results in enhanced metastatic phenotype that is correlated with loss of cellular junctions. Taken together, these results provide compelling evidence that 14-3-3σ is a potent tumor suppressor involved in ErbB2-driven breast cancer initiation and metastasis. 14-3-3σ has been identified as a normal mammary epithelial cell marker frequently downregulated during neoplastic development. Consistent with its potential role as a tumor suppressor, we demonstrate that targeted disruption of 14-3-3σ in a number of epithelial tissues can profoundly impact both the initiation and metastatic phases of ErbB2-mediated ...Continue Reading

References

Jul 1, 1992·British Journal of Cancer·P J HainsworthO M Garson
Jan 1, 1991·The Journal of Pathology·N M KernohanI D Miller
Mar 1, 1991·Genes, Chromosomes & Cancer·G StenmanP Sahlin
Jan 1, 1993·Medical and Pediatric Oncology·A G Knudson
Mar 29, 1996·The Journal of Biological Chemistry·C T GuyW J Muller
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I L AndrulisD McCready
Jul 11, 1998·Molecular Cell·H HermekingB Vogelstein
May 17, 2000·Proceedings of the National Academy of Sciences of the United States of America·A T FergusonS Sukumar
Mar 22, 2005·Molecular & Cellular Proteomics : MCP·Anne BenzingerHeiko Hermeking
Apr 29, 2005·Cell Research·Dmitri Lodygin, Heiko Hermeking
Oct 4, 2005·Nature Genetics·Bruce J HerronLinda D Siracusa
Oct 22, 2005·Proceedings of the National Academy of Sciences of the United States of America·Qiutang LiInder M Verma
May 16, 2006·Seminars in Cancer Biology·Dmitri Lodygin, Heiko Hermeking
Feb 15, 2008·The EMBO Journal·Josie Ursini-SiegelWilliam J Muller
May 5, 2010·Genes & Development·Chen LingWilliam J Muller

❮ Previous
Next ❯

Citations

Sep 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Aaron BoudreauMina J Bissell
Nov 29, 2016·Experimental Cell Research·Alyssa C Lesko, Jenifer R Prosperi
Jul 14, 2016·Oncotarget·Markus WinterHeiko Hermeking
Jul 22, 2019·International Journal of Molecular Sciences·Xiaolan FanMingyao Yang
Dec 22, 2016·Breast Cancer Research : BCR·Elizabeth A WellbergSteven M Anderson
May 16, 2012·Cancer Discovery·Nancy E Hynes, Tatiana Smirnova
Mar 5, 2016·Cancer Research·Pierre-Luc BoulayWilliam J Muller
Jul 1, 2021·Journal of Thrombosis and Haemostasis : JTH·Bal Krishan SharmaJoseph S Palumbo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.